Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 16/20 | 0.55 |
| ▸ | DHFR | P00374 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | F12 | P00748 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30422312 | 0.83 | DHFR (0.54) | PTGDR2DHFR | |
| SCHEMBL19617491 | 0.83 | DHFR (0.49) | PTGDR2DHFRMEN1ALDH1A1GAA | |
| SCHEMBL30422303 | 0.82 | DHFR (0.53) | PTGDR2DHFRMEN1ALDH1A1GAA | |
| SCHEMBL23854680 | 0.80 | DHFR (0.60) | DHFRMEN1KMT2AKDR | |
| SCHEMBL3337973 | 0.79 | TMEM97 (0.46) | PTGDR2DHFRMEN1ALDH1A1GAA | |
| SCHEMBL30420957 | 0.78 | TMEM97 (0.46) | PTGDR2DHFRMEN1ALDH1A1GAA | |
| SCHEMBL11091799 | 0.77 | DHFR (0.60) | PTGDR2DHFRMEN1KMT2AKDR | |
| SCHEMBL31091972 | 0.77 | DHFR (0.60) | PTGDR2DHFRMEN1KMT2AKDR | |
| SCHEMBL28096940 | 0.77 | TMEM97 (0.58) | PTGDR2MEN1ALDH1A1GAAMAPT | |
| SCHEMBL25021542 | 0.76 | TMEM97 (0.43) | PTGDR2DHFRMEN1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357277-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357277-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2023-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357277-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | PTGDR2 1730/4885DHFR 393/4885MEN1 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.